BiotechTube

DFA-02 + Placebo

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Surgical Site Infection

Conditions

Surgical Site Infection

Trial Timeline

Feb 1, 2012 → Jun 1, 2013

NCT ID
NCT01496352

About DFA-02 + Placebo

DFA-02 + Placebo is a phase 1/2 stage product being developed by Dr. Reddy's Laboratories for Surgical Site Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01496352. Target conditions include Surgical Site Infection.

What happened to similar drugs?

7 of 20 similar drugs in Surgical Site Infection were approved

Approved (7) Terminated (5) Active (10)
🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3
✅Epoetin alfa + Standard of CareJohnson & JohnsonApproved
✅ErtapenemMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅Deep neuromuscular blockMerckApproved
✅RocuroniumMerckApproved
🔄Sugammadex + Neostigmine + GlycopyrrolateMerckPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01496352Phase 1/2Completed

Competing Products

20 competing products in Surgical Site Infection

See all competitors
ProductCompanyStageHype Score
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
CelecoxibAstellas PharmaPre-clinical
26
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
Epoetin alfa + Standard of CareJohnson & JohnsonApproved
35
HR021618 + HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
31
SHR0410 Injection + Placebo for SHR0410 InjectionJiangsu Hengrui MedicinePhase 2
27
ErtapenemMerckApproved
43
Sugammadex + RocuroniumMerckApproved
43
Deep neuromuscular blockMerckApproved
43
RocuroniumMerckApproved
43
ErtapenemMerckPhase 2/3
38
Sugammadex + Neostigmine + GlycopyrrolateMerckPhase 3
40
Ecallantide + PlaceboMerckPhase 2
27
Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)Novo NordiskPhase 1
36
Insulin infusion with a goalNovo NordiskPhase 3
40
parecoxib/valdecoxibPfizerApproved
35
Tranexamic acid + Standard of CarePfizerApproved
43
Ibuprofen 250 mg / Acetaminophen 500 mg + Ibuprofen 250 mg + Acetaminophen 650 mg + PlaceboPfizerPhase 3
40
valdecoxib + valdecoxib/placebo + placeboPfizerPhase 3
40
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
27